Iridex Cuts 2026 Revenue Guidance to $46M-$48M as Q3 Sales Fall 19%
AiX — Free Expert Advisor
Trades XAUUSD on autopilot. Verified Myfxbook performance. Free forever.
Risk warning: CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. The majority of retail investor accounts lose money when trading CFDs. AiX is informational software — not investment advice. Past performance does not guarantee future results.
Iridex Corporation (Nasdaq: IRIX) cut its full-year 2026 revenue guidance to between $46 million and $48 million on 17 November 2026, down from a prior range of $51 million to $53 million, after third-quarter revenue fell 19% year over year to $10.2 million from $12.5 million. The San Jose-based maker of laser systems for glaucoma and retinal disease also reported third-quarter gross margin of 42.4%, up from 32.1% a year earlier, and a net loss of $1.4 million, or $0.08 per share, the company announced.
Context — why the guidance cut matters now
Iridex sells capital equipment and single-use probes into more than 100 countries, mostly through independent distributors outside the United States. That channel structure makes reported revenue sensitive to distributor ordering behavior rather than end-patient demand, and the company said the third-quarter shortfall came from both.
Patrick Mercer, Iridex president and CEO, said revenue "came in below our expectations this quarter," pointing to weaker customer demand in Europe and Asia plus order delays late in the period as distributors worked through probe inventory and faced regulatory hurdles. The company did not quantify the regional split of the decline.
The prior-year comparison carried an unusual drag. Iridex recorded a one-time write-off of roughly $0.8 million to cost of goods sold in the third quarter of 2025. Excluding that item, pro forma gross margin was 38.7% a year ago, which the company framed as a 370 basis point improvement to this year's 42.4%.
Management tied the margin gain to cost programs launched when Mercer became CEO, including a headquarters relocation to San Jose that the company expects to deliver about $600,000 in annualized savings. The company also said it is deep into a strategic review of its product lines and is reprioritizing resources toward its most profitable opportunities.
The macro backdrop is not disclosed in the report. No interest rate, index level, or currency assumption is given, and Iridex does not attribute the international softness to any named macro factor.
Data — what the numbers show
Revenue split three ways. Retina product revenue was $5.1 million, down from $6.7 million a year earlier. The Cyclo G6 glaucoma family generated $3.2 million, down from $3.5 million. Other revenue, which includes service and royalties, fell to $1.9 million from $2.2 million, partly because no royalty revenue was recorded in the quarter.
Unit volumes tell the same story. Iridex sold roughly 11,900 Cyclo G6 probes in the quarter versus 14,900 a year earlier, and 28 Cyclo G6 Glaucoma Laser Systems versus 30. The probe decline is the larger swing, since probes are the recurring consumable tied to installed systems.
| Metric | Q3 2026 | Q3 2025 |
|---|---|---|
| Total revenue | $10.2M | $12.5M |
| Gross margin | 42.4% | 32.1% |
| Net loss | $1.4M | $1.6M |
| Adjusted EBITDA | -$0.6M | -$0.1M |
| Cash and equivalents | $3.7M | not disclosed |
Operating expenses were $5.5 million, essentially flat against $5.4 million a year earlier. That flatness is why the smaller revenue base did not widen the net loss: gross profit actually rose to $4.3 million from $4.0 million despite the revenue decline.
Adjusted EBITDA moved the other way, to a loss of $0.6 million from a loss of $0.1 million a year earlier. The nine-month figures show adjusted EBITDA of -$0.7 million versus +$0.3 million for the same stretch of 2025.
Balance sheet pressure is visible in inventories, which climbed to $11.8 million from $7.9 million at the start of the fiscal year, and in cash, which fell $1.0 million sequentially to $3.7 million. Accounts receivable dropped to $4.8 million from $9.5 million at year start.
Analysis — what it means for markets and sectors
Iridex sits in a narrow slice of the medical device market: ophthalmic laser platforms competing against larger surgical and vision-care manufacturers that report on different fiscal calendars. The report names no peer, gives no competitor revenue, and provides no sector benchmark, so any cross-company comparison would require figures this report does not supply.
The mechanics of the miss matter more than the headline decline. Distributor destocking is a timing issue that can reverse; the company itself said it expects a "reversal of the inventory stocking process" in the fourth quarter. If that happens, reported revenue recovers without any change in underlying procedure volumes.
The counter-argument is that Iridex has now pointed to distributor inventory twice — once as a build, once as a drawdown. Repeated channel explanations invite skepticism about whether the underlying demand for probes is growing, especially with probe units down roughly 20% year over year.
Margin is the genuine bright spot. A 42.4% gross margin on a lower revenue base, with operating expenses flat, means the company's cost structure is shrinking faster than its sales. The planned shift of major products to third-party contract manufacturers is the next lever management named for 2027.
Cash is the binding constraint. A $3.7 million cash balance against a $1.0 million quarterly burn leaves limited room for error, and the company acknowledged it built safety stock inventory to manage its manufacturing transition. Positioning follows directly: holders are underwriting a margin-and-cash-flow story, not a growth story, and the guidance cut removes the growth case for now.
Outlook — what to watch next
Iridex said it expects fourth-quarter cash utilization to fall significantly on stronger sales and consumption of the safety stock inventory. That is the first checkpoint — whether the sequential cash draw lands below the $1.0 million recorded in the third quarter.
Adjusted operating expenses for fiscal 2026 are still guided to $19 million to $19.5 million, excluding depreciation, amortization, and stock-based compensation. Holding that line while revenue shrinks is what preserves the margin improvement.
The strategic review is the second checkpoint. Management said it expects to enter 2027 with better margins, a lower cost base, and a model better aligned toward cash flow generation, but gave no timeline for completing the review and no detail on which product lines could be cut or sold. The report also gives no fourth-quarter revenue figure and no 2027 guidance.
Management hosted a conference call at 2:00 p.m. PT on the day of the release. No specific date was given for the next scheduled financial update beyond the standard quarterly cycle.
Frequently Asked Questions
What does the Iridex guidance cut mean for retail investors?
It removes the revenue growth case from the near-term story. Full-year 2026 revenue is now expected at $46 million to $48 million instead of $51 million to $53 million, a reduction of roughly $5 million at both ends. What remains is a margin and cash-flow narrative: gross margin improved to 42.4%, operating expenses held flat, and management targets a lower cost base entering 2027.
Why did Iridex gross margin rise while revenue fell?
Two things. The prior-year quarter included a one-time write-off of about $0.8 million charged to cost of goods sold, which depressed the 32.1% comparison. Stripping that out, pro forma gross margin was 38.7%, so the underlying improvement is 370 basis points. The company also cited more favorable geographic mix and sustained pricing discipline, plus savings from cost programs including the headquarters move.
What happens next for Iridex in the fourth quarter?
The company expects cash utilization to decrease significantly, driven by stronger sales and the reversal of the inventory stocking process it described. It reiterated fiscal 2026 adjusted operating expenses of $19 million to $19.5 million. The strategic product-line review is ongoing, with no completion date disclosed, and no fourth-quarter revenue guidance or 2027 outlook was provided.
Bottom Line
Iridex traded revenue growth for margin, and the fourth quarter now has to prove the distributor-driven shortfall was timing, not demand.
Disclaimer: This article is for informational purposes only and does not constitute investment advice. CFD trading carries high risk of capital loss.
Trade XAUUSD on autopilot — free Expert Advisor
AiX is our free MetaTrader 5 Expert Advisor. Verified Myfxbook performance. No subscription. No fees. XAUUSD breakout engine.
PartnerPosition yourself for the macro moves discussed above
Start TradingSponsored
Ready to trade the markets?
Open a demo account in 30 seconds. No deposit required.
CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money.